Camrelizumab Combined with Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) As Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)

Sponsor
Shanghai Zhongshan Hospital
Study ID
NCT06796803
Phase
PHASE2/PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Potentially Resectable Hepatocellular Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this phase 2/3 study is to investigate the efficacy and safety of camrelizumab combined with rivoceranib and hepatic arterial infusion chemotherapy (HAIC) as conversion therapy for Potentially Resectable HCC.

Key Dates

Start date
Feb 20, 2025
Status verified
Jan 2025
Primary completion
Feb 20, 2028
Completion
Feb 28, 2030

Study Design

Enrollment
398 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: camrelizumab + rivoceranib + HAIC
  • Active Comparator: camrelizumab + rivoceranib

Primary Outcome Measure

R0 rate [ Time Frame: 24 months ]

Central Contacts